Indications: type 2 diabetes mellitus.
Increases sensitivity to insulin in muscle and
adipose tissue; inhibits hepatic gluconeogenesis.
Binds to PPARγ (peroxisome proliferator-activated receptor gamma).
Enhances effect of circulating insulin.
Troglitazone was withdrawn from the market because
of rare idiosyncratic hepatocellular toxicity.
Rosiglitazone: dose related reduction in Hb and WBC (increased plasma volume?).
Oedema. LFT monitoring recommended because of Troglitazone.
Does NOT produce hypoglycaemia.